Univariable

Multivariable

Supplementary Table: Behavioural and psychosocial characteristics and baseline demographic variables of users of daily oral PrEP (emtricitabine/tenofovir disoproxil), associated with TFV-DP concentration in linear regression analysis using generalised estimating equations. Sensistivity analysis excluding visits on which participants switched to event-driven PrEP (n=250; total number of DBS samples=440). AMPrEP study, Amsterdam, 2015-2018.

Univariable			Multivariable		
$\beta^a$	(95% CI)	p value	$\beta^a$	(95% CI)	p value
		0.0063			0.0014
35.4	(-248 to 319)		29.7	(-260 to 319)	
21.8	(-228 to 271)		28.5	(-226 to 283)	
131	(-120 to 382)		144	(-110 to 399)	
	(1.06 to 576)		308	(21.5 to 595)	
	(107 to 832)		496	(141 to 852)	
-88.6	(-253 to 76.0)	0.29			
-31.4	(-159 to 96.3)	0.63			
		0.74			
-24.1	(-166 to 118)				
0		0.30			
-123	(-462 to 216)				
129	(-61.8 to 320)				
0		0.97			
44.0	(-117 to 205)				
39.5	(-132 to 211)				
	,				
0		0.029			
29.8	(-95.8 to 155)				
-202	(-376 to -28.9)				
-17.6		0.77			
161	(14.5 to 308)	0.031			
-323	(-136 to 71.2)	0.54			
	,				
40.1	(-9.92 (0 90.1)	0.12			
25.3	(-16.1 to 66.7)	0.23			
191	(48.4 to 333)	0.0086	183	(50.5 to 315)	0.0068
-46.9	(-173 to 79.3)	0.47			
-5.53	(-105 to 93.6)	0.91			
-52.3		0.44			
	(,				
-49.2	(-171 to 73 0)	0.43			
<b>∓3.</b> ∠	(1711070.0)	0.40			
40.7	( 150 to 66 0)	0.50			
	,				
83.2	(-51.9 to 218)	0.23			
126	(2.01 to 251)	0.046	136	(18.5 to 253)	0.023
-67.7	(-131 to -4.77)	0.035	-76.1	(-139 to -13.4)	0.018
	35.4 21.8 131 288 469 -88.6 -31.4 0 -24.1 0 -123 129 0 44.0 39.5 0 29.8 -202 -17.6 161 -32.3 40.1 25.3 191 -46.9 -5.53 -52.3 -49.2 -42.7 104 83.2	β³ (95% CI)  35.4 (-248 to 319) 21.8 (-228 to 271) 131 (-120 to 382) 288 (1.06 to 576) 469 (107 to 832) -88.6 (-253 to 76.0)  -31.4 (-159 to 96.3)  0 -24.1 (-166 to 118)  0 -123 (-462 to 216) 129 (-61.8 to 320)  0 44.0 (-117 to 205) 39.5 (-132 to 211)  0 29.8 (-95.8 to 155) -202 (-376 to -28.9) -17.6 (-136 to 101) 161 (14.5 to 308)  -32.3 (-136 to 71.2) 40.1 (-9.92 to 90.1) 25.3 (-16.1 to 66.7) 191 (48.4 to 333)  -46.9 (-173 to 79.3) -5.53 (-105 to 93.6) -52.3 (-186 to 81.4)  -49.2 (-171 to 73.0)  -42.7 (-152 to 66.9) 104 (-70.3 to 278) 83.2 (-51.9 to 218)	β³         (95% CI)         p value           0.0063         35.4         (-248 to 319)         21.8         (-228 to 271)         131         (-120 to 382)         288         (1.06 to 576)         469         (107 to 832)         -88.6         (-253 to 76.0)         0.29           -31.4         (-159 to 96.3)         0.63         0         0.74           -24.1         (-166 to 118)         0         0.30           -123         (-462 to 216)         129         (-61.8 to 320)           0         0.97         0.97         0.97           44.0         (-117 to 205)         39.5         (-132 to 211)           0         0.029         0.98         (-95.8 to 155)         0.29           -29.8         (-95.8 to 155)         0.29         0.29           -29.8         (-95.8 to 155)         0.29           -17.6         (-136 to 101)         0.77           161         (14.5 to 308)         0.031           -32.3         (-136 to 71.2)         0.54           40.1         (-9.92 to 90.1)         0.12           25.3         (-16.1 to 66.7)         0.23           191         (48.4 to 333)         0.0086           -46.9	β³         (95% CI)         p value         β³           0.0063         35.4         (-248 to 319)         29.7           21.8         (-228 to 271)         28.5           131         (-120 to 382)         144           288         (1.06 to 576)         308           469         (107 to 832)         496           -88.6         (-253 to 76.0)         0.29           -31.4         (-159 to 96.3)         0.63           0         0.74           -24.1         (-166 to 118)           0         0.30           -123         (-462 to 216)           129         (-61.8 to 320)           0         0.97           44.0         (-117 to 205)           39.5         (-132 to 211)           0         0.029           29.8         (-95.8 to 155)           -202         (-376 to -28.9)           -17.6         (-136 to 101)         0.77           161         (14.5 to 308)         0.031           -32.3         (-136 to 71.2)         0.54           40.1         (-9.92 to 90.1)         0.12           25.3         (-16.1 to 66.7)         0.23           191 <td>β³         (95% CI)         p value         β²         (95% CI)           35.4         (-248 to 319)         29.7         (-260 to 319)           21.8         (-228 to 271)         28.5         (-26 to 283)           131         (-120 to 382)         144         (-110 to 399)           288         (1.06 to 576)         308         (21.5 to 595)           469         (107 to 832)         496         (141 to 852)           -88.6         (-253 to 76.0)         0.29         -31.4         (-159 to 96.3)         0.63           0         0.74         -24.1         (-166 to 118)         0.30         -123         (-462 to 216)         0.30           129         (-61.8 to 320)         0.97         44.0         (-117 to 205)         39.5         (-132 to 211)         0         0.029           29.8         (-95.8 to 155)         -202         (-376 to -28.9)         -17.6         (-136 to 101)         0.77         161         (14.5 to 308)         0.031           -32.3         (-136 to 71.2)         0.54         40.1         (-9.92 to 90.1)         0.12           25.3         (-16.1 to 66.7)         0.23           191         (48.4 to 333)         0.086         183</td>	β³         (95% CI)         p value         β²         (95% CI)           35.4         (-248 to 319)         29.7         (-260 to 319)           21.8         (-228 to 271)         28.5         (-26 to 283)           131         (-120 to 382)         144         (-110 to 399)           288         (1.06 to 576)         308         (21.5 to 595)           469         (107 to 832)         496         (141 to 852)           -88.6         (-253 to 76.0)         0.29         -31.4         (-159 to 96.3)         0.63           0         0.74         -24.1         (-166 to 118)         0.30         -123         (-462 to 216)         0.30           129         (-61.8 to 320)         0.97         44.0         (-117 to 205)         39.5         (-132 to 211)         0         0.029           29.8         (-95.8 to 155)         -202         (-376 to -28.9)         -17.6         (-136 to 101)         0.77         161         (14.5 to 308)         0.031           -32.3         (-136 to 71.2)         0.54         40.1         (-9.92 to 90.1)         0.12           25.3         (-16.1 to 66.7)         0.23           191         (48.4 to 333)         0.086         183

AMPrEP: Amsterdam PrEP demonstration project; DBS: dried blood spots; MHI-5: Mental Health Inventory-5; PrEP: pre-exposure prophylaxis; TFV-DP: tenofovir diphosphate.

<sup>&</sup>lt;sup>a</sup> TFV-DP concentration in DBS in fmol/punch; <sup>b</sup> 6 missing; <sup>c</sup> 27 missing; <sup>d</sup> 5 missing; <sup>e</sup> 2 missing; <sup>f</sup> 4 missing; <sup>g</sup> 14 missing; <sup>h</sup> 16 missing; <sup>i</sup> Use of γ-hydroxybutyrate, γ-Butyrolactone, methamphatamine or mephedrone prior to or during sex in the 3 months prior to inclusion into AMPrEP; <sup>j</sup> Indication of an anxiety or depressive mood disorder; <sup>k</sup> Indication of an alcohol use disorder, 15 missing; <sup>l</sup> Indication of a drug use disorder, 15 missing; <sup>m</sup> Scale 1-7, dichotomised, at baseline.